

BSE Code: 532531

NSE Code: STAR

Reuters Code: STAR:NS

Bloomberg Code: STR:IN

### Shasun and Arrow acquisition to drive the growth

Strides Shasun Limited (Strides) is a fully integrated global pharmaceutical company with business interests in developing niche and complex pharmaceutical products. With its presence in more than 85 countries, Strides is engaged in the manufacture of pharmaceutical dosage forms in branded as well generic categories. The company manufactures capsules, soft gelatin capsules, parenterals and semi-solids.

### Investment Rationale

☞ **Regulated markets business to witness traction:** In FY16, the growth in North American markets was driven by front-end operations while base portfolio delivered a strong performance with healthy market share for key products such as Vancomycin, Ergocalciferol, Methoxsalen, Calcitriol. Importantly, Strides has more than 120 products in the pipeline with a focus on Softgels, derma and extended release. The company expects to get 7-8 ANDA approvals in FY17E with an addressable market size of USD1bn (including Lovaza). Interestingly, approval for Lovaza (market size at USD 700 mn) is expected in FY17E, which will contribute significantly to the overall revenues due to limited competition in this space. Hence, we expect regulated markets to grow at a CAGR of 46% over FY16-18E primarily driven by Shasun's consolidation.

☞ **Africa to bolster Emerging markets revenue:** Strides witnessed improvement in African revenues on account of two factors: 1) higher growth in branded formulations during FY16 and 2) disciplined approach followed to counter the credit risks in a volatile operating environment. Branded business continues to post healthy growth while demand for generic products got impacted as few countries in Africa faced volatile currency environment. Going forward, African business is expected to grow consistently, driven by new product launches, enhanced sales force & local manufacturing base. Besides, it has comprehensive portfolio of product registrations across these markets and a robust pipeline of ~300 products that will be launched over next few years.

☞ **Shasun acquisition to aid growth ahead:** Shasun merger provides vertical integration benefits with better cost synergies and scale to strengthen institutional and US business. Before acquiring Shasun, Strides used to outsource API from third parties. However, consolidation of Shasun would help in de-risking the US product pipeline & also provide backward integration benefits for its regulated and institutional businesses. Moreover, Shasun and Arrow's acquisitions will diversify company's revenue mix with US and Africa being the key growth drivers.

**Valuation:** We expect Strides revenue and PAT to grow at a CAGR of 26% & 59% respectively over FY16-18E. Further, EBITDA margins are expected to improve by 570bps on account of Shasun's backward integration, key launches in FY17 coupled with incremental growth from recent acquisitions. Hence, we initiate Strides with BUY rating with a TP of Rs. 1,255 at 18x FY18E earnings.


### Market Data

<b>Rating</b>	<b>BUY</b>
<b>CMP (Rs.)</b>	1,093
<b>Target (Rs.)</b>	1,255
<b>Potential Upside</b>	15%
<b>Duration</b>	Long Term
Face Value (Rs.)	10
52 week H/L (Rs.)	1,412/848
Adj. all time High (Rs.)	1412
Decline from 52WH (%)	22.6
Rise from 52WL (%)	28.9
Beta	1.1
Mkt. Cap (Rs.Cr)	9,769

### Fiscal Year Ended

Y/E	FY15	FY16	FY17E	FY18E
Net sales (Rs.Cr)	1,196	3,156	4,345	4,996
Net profit (Rs.Cr)	9	246	435	623
EPS (Rs.)	1.5	27.5	48.7	69.7
P/E (x)	728.8	39.7	22.4	15.7
P/BV (x)	5.7	3.4	3.0	2.5
ROE (%)	0.8	12.3	14.2	17.6

### One year Price Chart



Shareholding Pattern	Mar-16	Dec-15	Chg.
Promoters (%)	31.1	31.0	0.1
Public (%)	68.9	69.0	0.1


**Strides is a fully integrated global pharmaceutical company with business interests in developing niche and complex pharmaceutical products**

**The company expects to get 7-8 ANDA approvals in FY17E with an addressable market size of USD1bn (including Lovaza).**

## Company overview

Strides Shasun Limited (Strides) is a fully integrated global pharmaceutical company with business interests in developing niche and complex pharmaceutical products. With its presence in more than 85 countries, Strides is engaged in the manufacture of pharmaceutical dosage forms in branded as well generic categories. The company manufactures capsules, soft gelatin capsules, parenterals and semi-solids. The Company also has a strong commercial platform to market its pharmaceutical products globally through front-end presence. The pharma generics business focuses on the key regulated markets of US, UK, Euro and Australia. Branded generics business caters to the emerging markets of India and Africa. Institutional business represents Company's business with global funding agencies for Anti-retroviral and Anti-malaria medicines.

### Revenue break-up



Source: Company, In-house research

## US to drive the regulated markets growth at CAGR of 46% over FY16-18E


Post divestment of Agila's business in 2013 (injectable segment), Strides became a small player in US with FY15 sales of just USD 19 mn. However, it has started its own front-end in the US and built a new R&D centre in Bangalore. In addition, the Shasun acquisition has provided Strides with a large complementary product pipeline. Strides is focusing on small off-patent products and derma in the complex generics.

Importantly, regulated markets contributed 34% to total revenues in FY16. In FY16, the growth in North American markets was driven by front-end operations while base portfolio delivered a strong performance with healthy market share for key products such as Vancomycin, Ergocalciferol, Methoxsalen, Calcitriol. Further, Strides has more than 120 products in the pipeline with a focus on Softgels, derma and extended release. The company expects to get 7-8 ANDA approvals in FY17E with an addressable market size of USD1 bn (including Lovaza). Interestingly, approval for Lovaza (market size at USD 700 mn) is expected in FY17E, which will contribute significantly to the overall revenues due to limited competition in this space. With the merger of Shasun, Strides revenue streams got geographically diversified across regulated markets in Europe and US. Strides is expected to file 20-25 ANDAs in FY17 & currently it has 29 ANDAs pending for approval. Hence, we expect regulated markets to grow at a CAGR of 46% over FY16-18E primarily driven by Shasun's consolidation.

**African business is expected to grow consistently, driven by new product launches, enhanced sales force & local manufacturing base.**

**The recent acquisitions of two CNS divisions (Rs92cr sales) of Sun Pharma and the J&J portfolio will provide incremental growth to the Indian business of Strides.**

#### Regulated markets to grow at a CAGR of 46% during FY16-18E



Source: Company, In-house research

#### Africa to drive emerging markets growth at 19% CAGR over FY16-18E

Strides has been one of the few Indian companies which has focused on African markets. While it has generic presence in 27 countries, it has branded presence in just 12 of these countries. Entered Africa in 1990 via the generic market, Strides started by supplying to partners and expanded the branded business to Nigeria, Ghana and other new geographies. It has six own manufacturing plants in Africa and is planning to set up more plants going ahead.

Strides witnessed improvement in African revenues on account of two factors: 1) higher growth in branded formulations during FY16 and 2) disciplined approach followed to counter the credit risks in a volatile operating environment. Branded business continues to post healthy growth while demand for generic products got impacted as few countries in Africa faced volatile currency environment. Going forward, African business is expected to grow consistently, driven by new product launches, enhanced sales force & local manufacturing base. Besides, it has comprehensive portfolio of product registrations across these markets and a robust pipeline of ~300 products that will be launched over next few years. Growth from generics will be faster than the branded space over FY16-20, driven by new product launches & increasing MR head-count (increasing field force from 220 to 1,000).


#### India: Inorganic growth to provide incremental revenues

Strides entered the Indian market through the Grandix acquisition in 2007, which provided Strides with the ReNerve brand. In 2014, Strides acquired brand Raricap (women's health portfolio) and the Indian Branded Generic Business of Bafna Pharmaceuticals to strengthen domestic brands business, which now has a pan-India reach. The recent acquisitions of two CNS divisions (Rs92cr sales) of Sun Pharma and the J&J portfolio will provide incremental growth to the Indian business of Strides. EMs business now has a strong product portfolio and a well-integrated field force which will provide levers to India's growth story. The company collaborated with Gilead Sciences Inc to produce generic sofosbuvir for chronic Hepatitis C. The collaboration enabled it to distribute medicines to 91 developing countries and it is one among the seven pharmaceutical companies in India (launched a generic drug Sofosbuvir in India, under the brand name Virso), who are licensed by Gilead Sciences Inc.

The company's investment in new markets of Russia, CIS and South East Asia is going to build a strong branded generics platform in the growing pharmaceuticals markets globally. We expect Strides EMs business to grow at a CAGR of 19% over FY16-18E on account of scale up in revenues from acquisitions coupled with the continuous traction in branded generics in Africa.

*The company develops and manufactures antiretroviral and antimalarial medicines to institutionally-funded projects.*

Emerging Markets revenue growth FY16-18E




### Institutional business: Shasun acquisition to provide backward integration

Institutional business contributed 19% to overall revenue in FY16. The company develops and manufactures antiretroviral and antimalarial medicines to institutionally-funded projects and Global Procurement Agencies, such as UNITAID, Global Drug Facility, PEPFAR and Clinton Foundation. It has multiple qualified WHO and USFDA sites for manufacturing ARV and antimalarial drugs. Currently it is working in collaboration with Medicines for Malaria Venture (MMV) for the development of rectal artesunate for pre-referral treatment of children with severe malaria. It has already signed a sub-licensing agreement with the Medicines Patent Pool (MPP) to develop Dolutegravir (DTG) for treatment of HIV in developing countries. Further, it has tied up with Gilead Sciences for development and distribution of Tenofovir Alafenamide (TAF) in developing economies.

Increased off take in ARV segment and strong supply chain execution for higher volumes in Anti-Malarial's helped to deliver paramount performance in FY16. Moreover, Strides gets access to Shasun's USFDA/WHO-approved finished dosage and API plant (one finished dosage, two API, one CRAMS) which would help it to scale operations and would see better EBITDA margin.

Institutional business to grow at CAGR of 25% during FY16-18E



Source: Company, In-house research

***APIs to grow at CAGR of 3% as complex natures of products are increasing towards captive consumption for formulations.***

## **PSAI: APIs captive consumption to increase due to front end expansion**

PSAI (Pharmaceutical Services and Active Ingredients) business contributed 33% to overall revenue in FY16 due to Shasun's acquisition. The company intends to use this division for backward integration and defocus on external sales. It has strong API manufacturing capability with 3 USFDA manufacturing facilities in India and UK. The company has aligned R&D function for API and formulations to ensure smooth finishing of backward integration plan for its key products across markets. In FY16, it has filed 5 new DMF's including 3 filed for captive use in line with formulations strategy and rationalized API portfolio for commodity products with focus on delivering higher margins. We expect APIs to grow at CAGR of 3% as complex natures of products are increasing towards captive consumption for formulations.

## **Key Risks:**


- Delay in key ANDA approvals from USFDA.
- Any adverse movement of global currencies vs INR
- USFDA scrutiny against the company's manufacturing plants regarding cGMP practices.

## Financials


### Revenue to grow at CAGR of 26% with EBITDA margin expansion of 570bps

We expect Strides' revenue to grow at a CAGR of 26%, driven by scale up of revenues due to multiple acquisitions (Shasun, Aspen's drug portfolio i.e. Arrow) coupled with new launches and. Hence, we expect 570bps improvements in EBITDA margin over FY16-18E led by API's integration & shift in mix of product portfolio.

#### Revenue to grow at a CAGR of 26% FY16-18E



#### EBITDA & PAT margin to improve by 570bps and 470bps respectively




Source: Company, In-house research

### Return ratios to improve significantly

We expect Strides' return ratios to improve further on account of healthy profitability coupled with strong revenue growth. While ROE is likely to improve from 12.3% in FY16 to 17.6% in FY18E, ROCE is projected to increase from 11.5% in FY16 to 15.4% in FY18E.

#### Return ratios on an uptrend



Source: Company, In-house research

## Profit & Loss Account (Consolidated)

Y/E (Rs. Cr)	FY15	FY16	FY17E	FY18E
<b>Total operating Income</b>	<b>1,196</b>	<b>3,156</b>	<b>4,345</b>	<b>4,996</b>
Raw Material cost	560	1,529	2,129	2,348
Employee cost	172	499	687	790
Other operating expenses	234	607	652	749
<b>EBITDA</b>	<b>229</b>	<b>521</b>	<b>877</b>	<b>1,109</b>
Depreciation	64	157	207	217
<b>EBIT</b>	<b>165</b>	<b>364</b>	<b>671</b>	<b>892</b>
Other Income	39	121	25	25
Interest cost	47	180	171	157
<b>Profit before tax</b>	<b>156</b>	<b>305</b>	<b>524</b>	<b>760</b>
Tax	148	72	89	137
<b>Profit after tax</b>	<b>8</b>	<b>233</b>	<b>435</b>	<b>623</b>
Minority Interests	(1)	(13)	-	-
P/L from Associates	-	-	-	-
<b>Adjusted PAT</b>	<b>9</b>	<b>246</b>	<b>435</b>	<b>623</b>
E/o income / (Expense)	836	(37)	-	-
<b>Reported PAT</b>	<b>845</b>	<b>209</b>	<b>435</b>	<b>623</b>

## Balance Sheet (Consolidated)

Y/E (Rs. Cr)	FY15	FY16	FY17E	FY18E
Paid up capital	60	89	89	89
Reserves and Surplus	1,085	2,774	3,167	3,749
Net worth	1,145	2,863	3,257	3,838
Minority interest	19	43	43	43
Total Debt	892	3,447	2,447	2,247
Other non-current liabilities	35	31	35	38
<b>Total Liabilities</b>	<b>2,090</b>	<b>6,384</b>	<b>5,781</b>	<b>6,166</b>
Total fixed assets	590	3,273	3,391	3,374
Capital WIP	146	175	50	50
Goodwill	137	177	177	177
Investments	630	1,304	104	104
Net Current assets	473	1,149	1,720	2,086
Deferred tax assets (net)	5	(15)	(15)	(15)
Other non-current assets	110	322	354	390
<b>Total Assets</b>	<b>2,090</b>	<b>6,384</b>	<b>5,781</b>	<b>6,166</b>

## Cash Flow Statement (Consolidated)

Y/E (Rs. Cr)	FY15	FY16	FY17E	FY18E
Pretax profit	992	268	524	760
Depreciation	64	157	207	217
Chg. in Working Capital	(96)	(708)	(278)	(224)
Others	(821)	59	146	132
Tax paid	(56)	(72)	(89)	(137)
<b>Cash flow from operating activities</b>	<b>83</b>	<b>(295)</b>	<b>510</b>	<b>748</b>
Capital expenditure	(242)	(2,869)	(200)	(200)
Chg. in investments	400	(674)	1,200	-
Other investing cashflow	(106)	121	25	25
<b>Cash flow from investing activities</b>	<b>52</b>	<b>(3,422)</b>	<b>1,025</b>	<b>(175)</b>
Equity raised/(repaid)	3	1,515	-	-
Debt raised/(repaid)	321	2,555	(1,000)	(200)
Dividend paid	(707)	(42)	(42)	(42)
Other financing activities	(38)	(180)	(171)	(157)
<b>Cash flow from financing activities</b>	<b>(421)</b>	<b>3,848</b>	<b>(1,213)</b>	<b>(399)</b>
Net chg in cash	(286)	131	322	174

## Key Ratios (Consolidated)

Y/E	FY15	FY16	FY17E	FY18E
<b>Growth (%)</b>				
Net Sales	(10.8)	163.9	37.6	15.0
EBITDA	2.4	127.8	68.3	26.4
Net profit	(104.3)	2,648.9	77.1	43.2
<b>Margin (%)</b>				
EBITDA	19.1	16.5	20.2	22.2
EBIT	13.8	11.5	15.4	17.9
NPM	0.7	7.8	10.0	12.5
<b>Return Ratios (%)</b>				
RoE	0.8	12.3	14.2	17.6
RoCE	11.0	11.5	11.5	15.4
<b>Per share data (Rs.)</b>				
EPS	1.5	27.5	48.7	69.7
DPS	107.9	4.0	4.0	4.0
<b>Valuation(x)</b>				
P/E	728.8	39.7	22.4	15.7
EV/EBITDA	31.8	24.8	13.2	10.1
EV/Net Sales	6.1	4.1	2.7	2.3
P/B	5.7	3.4	3.0	2.5
<b>Turnover Ratios (x)</b>				
Net Sales/GFA	1.3	1.3	1.1	1.2
Sales/Total Assets	0.5	0.6	0.6	0.7

## Rating Criteria

Large Cap.	Return	Mid/Small Cap.	Return
<b>Buy</b>	More than equal to 10%	<b>Buy</b>	More than equal to 15%
<b>Hold</b>	Upside or downside is less than 10%	<b>Accumulate*</b>	Upside between 10% & 15%
<b>Reduce</b>	Less than equal to -10%	<b>Hold</b>	Between 0% & 10%
		<b>Reduce/sell</b>	Less than 0%

\* To satisfy regulatory requirements, we attribute 'Accumulate' as Buy and 'Reduce' as Sell.

\* Strides Shasun is a mid-cap company

## Disclaimer:

The SEBI registration number is INH200000394.

The analyst for this report certifies that all the views expressed in this report accurately reflect his / her personal views about the subject company or companies, and its / their securities. No part of his / her compensation was / is / will be, directly / indirectly related to specific recommendations or views expressed in this report.

This material is for the personal information of the authorized recipient, and no action is solicited on the basis of this. It is not to be construed as an offer to sell, or the solicitation of an offer to buy any security, in any jurisdiction, where such an offer or solicitation would be illegal.

We have reviewed the report, and in so far as it includes current or historical information, it is believed to be reliable, though its accuracy or completeness cannot be guaranteed. Neither Wealth India Financial Services Pvt. Ltd., nor any person connected with it, accepts any liability arising from the use of this document. The recipients of this material should rely on their own investigations and take their own professional advice. Price and value of the investments referred to in this material may go up or down. Past performance is not a guide for future performance.

We and our affiliates, officers, directors, and employees worldwide:

1. Do not have any financial interest in the subject company / companies in this report;
2. Do not have any actual / beneficial ownership of one per cent or more in the company / companies mentioned in this document, or in its securities at the end of the month immediately preceding the date of publication of the research report, or the date of public appearance;
3. Do not have any other material conflict of interest at the time of publication of the research report, or at the time of public appearance;
4. Have not received any compensation from the subject company / companies in the past 12 months;
5. Have not managed or co-managed the public offering of securities for the subject company / companies in the past 12 months;
6. Have not received any compensation for investment banking, or merchant banking, or brokerage services from the subject company / companies in the past 12 months;
7. Have not served as an officer, director, or employee of the subject company;
8. Have not been engaged in market making activity for the subject company;

This document is not for public distribution. It has been furnished to you solely for your information, and must not be reproduced or redistributed to any other person.

## Contact Us:

### Funds India

Uttam Building, Third Floor|

No. 38 & 39| Whites Road|

Royapettah| Chennai – 600014|

T: +91 7667 166 166

Email: [contact@fundsindia.com](mailto:contact@fundsindia.com)



## Dion's Disclosure and Disclaimer

I, Abhishek Kumar Das, employee of Dion Global Solutions Limited (Dion) is engaged in preparation of this report and hereby certify that all the views expressed in this research report (report) reflect my personal views about any or all of the subject issuer or securities.

### Disclaimer

This report has been prepared by Dion and the report & its contents are the exclusive property of the Dion and the client cannot tamper with the report or its contents in any manner and the said report, shall in no case, be further distributed to any third party for commercial use, with or without consideration.

Recipient shall not further distribute the report to a third party for a commercial consideration as this report is being furnished to the recipient solely for the purpose of information.

Dion has taken steps to ensure that facts in this report are based on reliable information but cannot testify, nor make any representation or warranty, express or implied, to the accuracy, contents or data contained within this report. It is hereby confirmed that wherever Dion has employed a rating system in this report, the rating system has been clearly defined including the time horizon and benchmarks on which the rating is based.

Descriptions of any company or companies or their securities mentioned herein are not intended to be complete and this report is not, and should not be construed as an offer or solicitation of an offer, to buy or sell any securities or other financial instruments. Dion has not taken any steps to ensure that the securities referred to in this report are suitable for any particular investor. This report is not to be relied upon in substitution for the exercise of independent judgment. Opinions or estimates expressed are current opinions as of the original publication date appearing on this report and the information, including the opinions and estimates contained herein, are subject to change without notice. Dion is under no duty to update this report from time to time.

Dion or its associates including employees engaged in preparation of this report and its directors do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report, including but not restricted to, fluctuation in the prices of securities, changes in the currency rates, diminution in the NAVs, reduction in the dividend or income, etc.

The investments or services contained or referred to in this report may not be suitable for all equally and it is recommended that an independent investment advisor be consulted. In addition, nothing in this report constitutes investment, legal, accounting or tax advice or a representation that any investment or strategy is suitable or appropriate to individual circumstances or otherwise constitutes a personal recommendation of Dion.

### REGULATORY DISCLOSURES:

Dion is engaged in the business of developing software solutions for the global financial services industry across the entire transaction lifecycle and inter-alia provides research and information services essential for business intelligence to global companies and financial institutions. Dion is listed on BSE Limited (BSE) and is also registered under the SEBI (Research Analyst) Regulations, 2014 (SEBI Regulations) as a Research Analyst vide Registration No. INH100002771. Dion's activities were neither suspended nor has it defaulted with requirements under the Listing Agreement and / or SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 with the BSE in the last five years. Dion has not been debarred from doing business by BSE / SEBI or any other authority.

In the context of the SEBI Regulations, we affirm that we are a SEBI registered Research Analyst and in the course of our business, we issue research reports /research analysis etc that are prepared by our Research Analysts. We also affirm and undertake that no disciplinary action has been taken against us or our Analysts in connection with our business activities.

In compliance with the above mentioned SEBI Regulations, the following additional disclosures are also provided which may be considered by the reader before making an investment decision:

1. Disclosures regarding Ownership

Dion confirms that:

- (i) Dion/its associates have no financial interest or any other material conflict in relation to the subject company (ies) covered herein at the time of publication of this report.
- (ii) It/its associates have no actual / beneficial ownership of 1% or more securities of the subject company (ies) covered herein at the end of the month immediately preceding the date of publication of this report.

Further, the Research Analyst confirms that:

- (i) He, his associates and his relatives have no financial interest in the subject company (ies) covered herein, and they have no other material conflict in the subject company at the time of publication of this report.
- (ii) he, his associates and his relatives have no actual/beneficial ownership of 1% or more securities of the subject company (ies) covered herein at the end of the month immediately preceding the date of publication of this report.

2. Disclosures regarding Compensation:

During the past 12 months, Dion or its Associates:

(a) Have not managed or co-managed public offering of securities for the subject company (b) Have not received any compensation for investment banking or merchant banking or brokerage services from the subject company (c) Have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject. (d) Have not received any compensation or other benefits from the subject company or third party in connection with this report

3. Disclosure regarding the Research Analyst's connection with the subject company:

It is affirmed that I, Abhishek Kumar Das employed as Research Analyst by Dion and engaged in the preparation of this report have not served as an officer, director or employee of the subject company

4. Disclosure regarding Market Making activity:

Neither Dion /its Research Analysts have engaged in market making activities for the subject company.

Copyright in this report vests exclusively with Dion.